8-K: Eyenovia Secures $1.9 Million in Registered Direct Offering to Advance Optejet Technology

Eyenovia, Inc. has announced a registered direct offering expected to generate approximately $1.9 million to support working capital, debt repayment, and the development of its Optejet device.

Summary

• Eyenovia, Inc. entered into a securities purchase agreement for a registered direct offering.
• The offering includes 11,000,000 shares of common stock, pre-funded warrants for up to 9,085,025 shares, and warrants for up to 40,170,050 shares.
• The combined offering price is $0.0969 per share and accompanying warrants, and $0.0968 per pre-funded warrant and accompanying warrants.
• The warrants are exercisable after stockholder approval, with an exercise price of $0.0969 per share and a five-year term.
• Pre-funded warrants are immediately exercisable at $0.0001 per share.
• The gross proceeds from the offering are expected to be approximately $1.95 million.
• The company intends to use the net proceeds for working capital, general corporate purposes, partial debt repayment, and advancement of the Optejet device.
• The offering is expected to close on or about December 9, 2024.
• Chardan Capital Markets, LLC is the placement agent for the offering.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is raising needed capital and has a promising technology, the dilution of shares and the need for debt repayment temper the overall outlook. The management's optimism is a positive sign, but the company still faces significant risks.

Positives

• The capital raise provides necessary funds for working capital and general corporate purposes.
• The funds will support the advancement of the next-generation Optejet device.
• The offering allows for partial repayment of debt with Avenue Capital Management II, L.P.
• The company is exploring strategic alternatives to maximize value.
• The company is engaged in productive discussions with multiple potential strategic partners.

Negatives

• The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders.
• The company is relying on a capital raise to fund operations and development.
• The company is partially using the funds to repay debt, indicating existing financial obligations.
• The warrants are exercisable after stockholder approval, which introduces a potential delay.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to clinical trials and market acceptance.
• The company's ability to raise additional funds as and when necessary is a risk.
• The company's reliance on third parties for development and commercialization poses a risk.
• The company faces intellectual property risks and competition.
• The company's stock price is currently trading below the minimum bid price required under the listing rules of the Trading Market.

Future Outlook

The company expects the funds from this offering, along with restructuring efforts, to allow them to continue developing the Gen-2 Optejet device, with a goal of registering it in the U.S. in the third quarter of 2025. They are also exploring strategic partnerships and expanding the device's capabilities.

Management Comments

• Michael Rowe, Chief Executive Officer of Eyenovia, stated, 'We expect the funds from this offering, together with our previously announced restructuring that is intended to right-size our organization, to allow us to continue to advance the development of our Gen-2 Optejet device, with the goal of registering that device in the United States in the third quarter of 2025.'
• Michael Rowe also mentioned that the company is focused on expanding the capabilities of the Gen-2 device to be consumer-filled with standard eye drops.
• He also noted that the Optejet is generating significant interest among potential strategic partners and that they are engaged in productive discussions with multiple parties, including their lender, Avenue Capital.
• Michael Rowe stated, 'I remain optimistic as we continue to work to maximize the value of the Gen-2 device and Eyenovia as a whole.'

Industry Context

This announcement comes as Eyenovia continues to develop its proprietary Optejet technology, which is aimed at improving the delivery of ophthalmic medications. The company is positioning itself to compete in the market for chronic front-of-the-eye diseases by offering a more convenient and potentially more effective alternative to traditional eye drops. The company is also exploring strategic partnerships, which is a common strategy in the biotech industry to accelerate development and commercialization.

Comparison to Industry Standards

• The offering is a registered direct offering, which is a common method for small-cap biotech companies to raise capital.
• The use of proceeds for working capital, debt repayment, and product development is typical for companies in this stage of development.
• The inclusion of warrants in the offering is a common incentive for investors in these types of transactions.
• The company's focus on strategic partnerships is consistent with industry trends, where collaborations are often used to leverage resources and expertise.
• The company's focus on the Optejet device and its potential for improved drug delivery aligns with the industry's push for more patient-friendly and effective treatments.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may benefit from the company's continued operations and development.
• Customers may benefit from the development of the Optejet device and its potential for improved treatment options.
• Creditors, such as Avenue Capital Management II, L.P., may receive partial debt repayment.
• Suppliers may benefit from the company's continued operations and development.

Next Steps

• The company will close the offering on or about December 9, 2024.
• The company will use the net proceeds for working capital, debt repayment, and advancement of the Optejet device.
• The company will seek stockholder approval for the warrants to become exercisable.
• The company will continue to explore strategic alternatives and partnerships.
• The company will continue to develop the Gen-2 Optejet device with the goal of registering it in the U.S. in the third quarter of 2025.

Key Dates

Keywords

registered direct offering, common stock, pre-funded warrants, warrants, Optejet, capital raise, debt repayment, working capital, Mydcombi, clobetasol propionate, strategic alternatives, ophthalmic technology